



Atty. Dkt. No. 078883-0145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philippa RADCLIFFE et al.
Title: TRANSGENIC ORGANISM
Appl. No.: 10/082,122
Filing Date: 02/26/2002
Examiner: Unassigned
Art Unit: 1632

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.



Atty. Dkt. No. 078883-0145

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding United Kingdom application. A copy of the United Kingdom Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

Jan 16, 2003

By

Michele M. Simkin

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538

Facsimile: (202) 672-5399

Michele M. Simkin

Attorney for Applicants

Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: 01/16/2003

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/082,122
 Filing Date 02/26/2002
 First Named Inventor Philippa RADCLIFFE et al.
 Group Art Unit 1632
 Examiner Name Unassigned
 Attorney Docket Number 078883-0145

JAN 16 2003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A1	WO	01/44458	A2	NOVARTIS AG	06/21/2001	
	A2	WO	00/73482	A1	CHIRON CORP. ET AL.	12/07/2000	
	A3	WO	98/51810	A1	UNI. NORTH CAROLINA	11/19/1998	

RECEIVED

JAN 17 2003

TECH CENTER 1600 2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	TARANTAL ET AL., "Lentiviral Vector Gene Transfer into Fetal Rhesus Monkeys (<i>Macaca mulatta</i>) <i>Mol. Ther.</i> (2001), Vol. 4, No. 6, pp. 614-621.	
	A5	WOLFGANG ET AL., "Rhesus monkey placental transgene expression after lentiviral gene transfer into preimplantation embryos," <i>Proc. Natl. Acad. Sci. USA</i> (2001), Vol. 98, No. 19, pp. 10728-10732.	
	A6	STEIN ET AL., "In Vivo Treatment of Hemophilia A and Mucopolysaccharidosis Type VII Using Nonprimate Lentiviral Vectors," <i>Mol. Ther.</i> (2001), Vol. 3, pp. 850-856.	
	A7	BERKOWITZ ET AL., "Construction and Molecular Analysis of Gene Transfer Systems Derived from Bovine Immunodeficiency Virus," <i>J. Virol.</i> (2001), Vol. 75, No. 7, pp. 3371-3382.	
	A8	TARANTAL ET AL., "Rhesus Monkey Model for Fetal Gene Transfer: Studies with Retroviral-Based Vector Systems," <i>Mol. Ther.</i> (2001), Vol. 3, No. 2, pp. 128-138.	

Examiner Signature

Date Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.